Should You Worry That Encompass Health's CEO Sold Into a Rally? Here's What to Know

Key Points The transaction involved 173,148 shares sold at a weighted average price of $125.47, totaling approximately $21.7 million. This disposition represents 39% of the CEO's direct common stock holdings in the company. The filing confirms all transacted shares were held directly. 10 stocks we like better than Encompass Health › Encompass Health Corporation (NYSE:EHC) President and CEO Mark J. Tarr reported a sale of about 173,000 shares of common stock on August 10, according to a recent SEC Form 4 filing . Transaction summary Metric Value Transaction date August 10, 2026 Shares sold 173,148 Transaction value $21.7 million Post-transaction shares (directly held) 267,814 Post-transaction value $33.69 million Transaction value based on SEC Form 4 weighted average sale price ($125.47); post-transaction value based on the August 10 market close ($125.81). Key questions What were the specific execution details for this transaction? The shares were sold in multiple transactions at prices ranging from $124.93 to $126.22, with the reporting person providing weighted average data for two distinct price bands in the filing. How does this sale impact the CEO's overall equity stake? The disposition reduced Tarr's direct common stock position by 39%, though he maintains a significant remaining stake of 268,000 shares valued at more than $33 million. What is the broader operational context for Encompass Health? Headquartered in Birmingham, the company operates across two primary divisions, Inpatient Rehabilitation and Home Health and Hospice, and currently maintains a market capitalization of $12.5 billion. Does the insider have any remaining indirect beneficial interest? No, the CEO's total beneficial ownership of 267,814 shares consists entirely of direct holdings, with no shares reported in indirect accounts or other share classes. Company Overview Metric Value Share Price (as of market close 2026-08-10) $125.81 Market Capitalization $12.5 billion Revenue (TTM) $6.2 billion Net Income (TTM) $621.0 million Company Snapshot Encompass Health Corporation operates a diversified post-acute healthcare platform delivering inpatient rehabilitation services and home health and hospice care across the United States through both dedicated facilities and in-home settings. The company generates revenue through its two primary divisions: Inpatient Rehabilitation, which provides focused recovery treatment on an inpatient and outpatient basis, and Home Health and Hospice, which delivers care services directly to patients in their residences. Encompass Health serves patients transitioning from acute care settings, including those recovering from significant illnesses, surgeries, and injuries, with a customer base comprised of healthcare systems, insurance providers, and individual patients requiring post-acute care services. Encompass Health Corporation is a leading operator in the post-acute healthcare sector with a market capitalization of $12.5 billion and TTM revenues of $6.2 billion, positioning the company as a significant provider of rehabilitation and home-based care services. The company's diversified business model across inpatient facilities and home health services provides revenue stability and exposure to the growing demand for post-acute care driven by an aging population and the shift toward value-based care delivery. With over 40,000 employees and a strong net income margin of approximately 10% on TTM revenues, Encompass Health maintains operational scale and profitability in a fragmented market characterized by consolidation opportunities. What this transaction means for investors Tarr didn't have shares withheld for taxes here, and there's no plan noted; he chose to sell, and he parted with about 39% of his direct stake in a single stretch, a meaningful cut for a sitting CEO. He did it days after Encompass Health's stock jumped on strong earnings, near a 52-week high, so he sold into strength. He still holds around 268,000 shares worth more than $33 million, which keeps him well aligned, but a sale this size deserves noting rather than dismissing. That said, the sale doesn't appear to signal trouble at the company. Encompass reported earlier this month that revenue rose about 10% to $1.6 billion, raised its full-year guidance for the second time this year, and lifted both its dividend and buyback authorization to $1 billion. Demand for its rehabilitation hospitals keeps climbing as the population ages, and in the earnings release, Tarr said the company was "very pleased with our second quarter results." Ultimately, the most likely read here is a CEO taking some money off the table after a strong run, not a warning, though a steep cut is worth watching for whether more follows. Should you buy stock in Encompass Health right now? Before you buy stock in Encompass Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Encompass Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $421,511 !* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,381,960 !* Now, it’s worth noting Stock Advisor’s total average return is 981 % — a market-crushing outperformance compared to 216% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor , and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of August 16, 2026. Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .

The transaction involved 173,148 shares sold at a weighted average price of $125.47, totaling approximately $21.7 million.

This disposition represents 39% of the CEO's direct common stock holdings in the company.

The filing confirms all transacted shares were held directly.

Encompass Health Corporation (NYSE:EHC) President and CEO Mark J. Tarr reported a sale of about 173,000 shares of common stock on August 10, according to a recent SEC Form 4 filing .

Transaction value based on SEC Form 4 weighted average sale price ($125.47); post-transaction value based on the August 10 market close ($125.81).

Encompass Health Corporation is a leading operator in the post-acute healthcare sector with a market capitalization of $12.5 billion and TTM revenues of $6.2 billion, positioning the company as a significant provider of rehabilitation and home-based care services. The company's diversified business model across inpatient facilities and home health services provides revenue stability and exposure to the growing demand for post-acute care driven by an aging population and the shift toward value-based care delivery. With over 40,000 employees and a strong net income margin of approximately 10% on TTM revenues, Encompass Health maintains operational scale and profitability in a fragmented market characterized by consolidation opportunities.

Tarr didn't have shares withheld for taxes here, and there's no plan noted; he chose to sell, and he parted with about 39% of his direct stake in a single stretch, a meaningful cut for a sitting CEO. He did it days after Encompass Health's stock jumped on strong earnings, near a 52-week high, so he sold into strength. He still holds around 268,000 shares worth more than $33 million, which keeps him well aligned, but a sale this size deserves noting rather than dismissing. That said, the sale doesn't appear to signal trouble at the company. Encompass reported earlier this month that revenue rose about 10% to $1.6 billion, raised its full-year guidance for the second time this year, and lifted both its dividend and buyback authorization to $1 billion. Demand for its rehabilitation hospitals keeps climbing as the population ages, and in the earnings release, Tarr said the company was "very pleased with our second quarter results." Ultimately, the most likely read here is a CEO taking some money off the table after a strong run, not a warning, though a steep cut is worth watching for whether more follows.